Mounjaro®
Starting from £179.99/mo
Start journey Learn moreChest pain on Mounjaro can have several causes, and the right response depends on the type of discomfort you're experiencing. Some chest sensations during tirzepatide treatment are linked to the medicine's well-known gastrointestinal effects and settle without intervention; others are warning signs that need same-day medical attention. Knowing which is which is the decision this page is here to help you make. Mounjaro is a prescription-only medicine, and your prescriber or the Patient Information Leaflet should be your first port of call for anything that feels serious or persistent.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common source of chest discomfort reported by people taking tirzepatide is the stomach and oesophagus, not the heart. Mounjaro slows gastric emptying as part of how it reduces appetite, and this can lead to acid reflux, indigestion, burping, and a sensation of pressure or tightness behind the breastbone — especially in the first few weeks of treatment or after a dose increase.
These GI-related symptoms tend to arrive alongside other familiar signs: bloating, nausea, an uncomfortably full feeling after small amounts of food, or gas-related pain in the stomach or abdomen. They are generally mild to moderate, and they often ease as the body adjusts. Eating smaller portions, staying upright after eating, and avoiding fatty or highly processed food can all help.
A quick self-check worth doing: sit up straight and take two or three slow breaths. If the discomfort shifts, reduces, or is clearly linked to having eaten recently, a GI cause is more likely. This is not a diagnostic test, but it takes under a minute and can help you describe the pattern clearly when you speak to a clinician. The NHS tirzepatide medicines page lists indigestion and reflux among the common side effects reported during clinical trials.
That said, if you are unsure, or if the chest discomfort is anything beyond mild and transient, do not wait. Contact your prescriber, call 111, or seek emergency care as the situation warrants.
Two conditions associated with GLP-1 receptor agonists can produce pain that reaches into the chest or upper abdomen and should not be dismissed as ordinary indigestion.
The first is acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 specifically to remind patients and clinicians that pancreatitis is a known but infrequent risk with GLP-1 medicines including tirzepatide. The hallmark symptom is severe, persistent stomach pain that spreads to your back, sometimes accompanied by vomiting. This is not the mild queasiness that fades after an hour. If you experience this pattern, stop eating and drinking and seek urgent medical help the same day. You can also report suspected side effects through the MHRA Yellow Card scheme.
The second is gallbladder disease, which is more common in people losing weight rapidly and has been observed in GLP-1 trials. Gallbladder pain typically presents as a sharp or cramping sensation in the upper right abdomen, but it can radiate up toward the right shoulder blade or across the chest. It often comes in waves and may follow a fatty meal.
Neither condition is common, but both are serious. Prompt assessment by a doctor is the right response to either.
Mounjaro is prescribed as part of a weight management plan, and the population taking it often has comorbidities (high blood pressure, dyslipidaemia, or cardiovascular history among them) that create their own cardiac risk independent of the medicine. Tirzepatide does not increase cardiovascular risk based on current trial data, but it does not make cardiac symptoms less relevant.
Call 999 immediately if chest pain is accompanied by any of the following: breathlessness, pain spreading to your arm, jaw, or neck, sweating, light-headedness, or a sense that something is seriously wrong. These are not symptoms to monitor from the sofa. Do not drive yourself to hospital.
If you take Mounjaro and want to understand the full picture of side effects, including some of the less-discussed ones such as changes in vision or leg or joint discomfort, it is worth reading through the Patient Information Leaflet that comes with your pen. Your prescriber can also talk through what to watch for at your dose level.
It is entirely reasonable to feel unsettled if you experience any new or unexplained chest sensation while on treatment. That feeling is worth acting on, not suppressing. Contact whoever prescribed for you (your GP or your online prescriber) and describe exactly what you felt, when it happened, and how long it lasted.
If you are considering starting Mounjaro and want to understand the side-effect profile before you commit, reading about how tirzepatide works is a sensible first step. For a broader look at all available weight management options, the weight loss treatments overview sets out what is currently licensed in the UK.
For patients already on treatment who have questions about cost (for example, following Eli Lilly's UK price changes in late 2025) those are separate concerns from safety, and it is worth not letting one get tangled up with the other.
Side effects like excess wind and bloating are inconvenient; potential cardiac or pancreatic symptoms are a different category entirely. Treat them differently. If, after reading and checking with your prescriber, you feel reassured and want to explore whether Mounjaro is right for you, check your eligibility with our clinical team at any time.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.